Alexander Sarah, Li Shannon, Tracy Melissa
Community Care Network, Inc., Munster, IN, United States of America.
RUSH University Medical Center, Chicago, IL, United States of America.
Am Heart J Plus. 2022 Mar 8;13:100108. doi: 10.1016/j.ahjo.2022.100108. eCollection 2022 Jan.
In the United States and worldwide, the leading cause of death in females is cardiovascular disease (CVD). However, compared to males, females have overall higher mortality rates, especially within the first few years of having an acute myocardial infarction (AMI). Despite the increased awareness of CVD in females and established benefits of cardiac rehabilitation (CR) programs, there is still delayed initiation of care, under-recognition of atypical presentations of angina in females, under referral of females to CR, and under-representation of females in CVD trials. In this paper, we will investigate the barriers to female participation in CR, explore the fundamental differences in physiology between males and females, and current limitations in CVD trials where females are under-represented. Finally, we aim to provide potential methods to increase enrollment of females in CR and CR related trials.
在美国及全球范围内,女性的主要死因是心血管疾病(CVD)。然而,与男性相比,女性的总体死亡率更高,尤其是在急性心肌梗死(AMI)后的头几年内。尽管女性对心血管疾病的认识有所提高,且心脏康复(CR)计划已证实具有益处,但仍存在护理启动延迟、女性心绞痛非典型表现未得到充分认识、女性被转介至心脏康复的比例较低以及女性在心血管疾病试验中的代表性不足等问题。在本文中,我们将研究女性参与心脏康复的障碍,探讨男性和女性在生理上的根本差异,以及女性代表性不足的心血管疾病试验中的当前局限性。最后,我们旨在提供增加女性参与心脏康复及相关试验的潜在方法。